Brief: BioInvent Presents Positive First Clinical Data On Anti-FcyRIIB Antibody BI-1607

BioInvent International AB

05/12/2023 14:21

Dec 5 (Reuters) - BioInvent International AB  BINV.ST :
    * BIOINVENT PRESENTS POSITIVE FIRST CLINICAL DATA ON
ANTI-FCYRIIB
ANTIBODY BI-1607
    * PHASE 1 DATA FROM 18 PATIENTS TREATED WITH BI-1607 IN
COMBINATION WITH TRASTUZUMAB PRESENTED AT SAN ANTONIO BREAST
CANCER SYMPOSIUM
    * BI-1607 WELL TOLERATED WITH NO SERIOUS ADVERSE EVENTS, AT
DOSES
OF 75-900MG
    * STABLE DISEASE HAVE BEEN OBSERVED IN 6/11 EVALUABLE
PATIENTS WHO
HAD PREVIOUSLY PROGRESSED AFTER TRASTUZUMAB CONTAINING LINES OF
TREATMENT

Source text for Eikon:  ID:nMFN8wM8h6 
Further company coverage:  BINV.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))